Sessions

Moving the Industry Towards Automated Systems for Scale-up Success
Workforce of the Future: Talent, Change Management and Enabling Future Development
Delivering Projects and Managing Timelines in the Variable, Continuously Changing Environment Of Cell and Gene Therapy
How to Market my Biotech to Investors: Lessons Learned from Successful Investment and Funding Rounds
Patient and Payer Challenges: Enabling Access to Patients through Market Access, Pricing and Patient-Led Discussion
Tech Review: New Platforms and Closed-Systems to Enable Commercial Success
Working With a CDMO is not Just an Outsourcing Contract but a Partnership: Learnings from Successful Biotech/CDMO Partnerships
Overcoming Challenges and Setting Up for Success on the Path to Commercialisation
Overcoming Challenges and Setting Up for Success on the Path to Commercialisation

Moving the Industry Towards Automated Systems for Scale-up Success

27 Jan 2022
15:30
SPONSORED BY
AmplifyBio
TTP
Pall Corporation

15:30  Chairperson’s Opening
J Kelly Ganjei, President & Chief Executive Officer, AmplifyBio

15:35  The Value of Automated, Closed-Systems in CGT Manufacturing

  • In this presentation, Kim Raineri will explore the value of automated, closed manufacturing systems
  • Advantages of automation for consistency, transfer and scalability
  • Advantages of closed systems for safety and efficiency
  • Impact of automation and closed systems on cost of goods
  • Case study of AVROBIO’s approach to automated, closed-system manufacturing

Kim Raineri, Chief Manufacturing and Technology Officer, AVROBIO

15:55  Process Analytical Technologies (PAT) and Automation in Bioprocessing

  • PAT and technology benefits within bioprocessing
  • MVDA (multivariate data analytics) and modeling utilization for real-time monitoring and feedback control
  • PAT orchestration including automation framework

Edita Botonjic-Sehic, Director of Analytics, Pall Corporation

16:15  Lessons Learned From Developing Automated Systems for Industrialised Processing of Autologous Cell Therapies

Dan Strange, Head of Cell Therapy Technology, TTP plc

16:35  Speaker Q&A and Panel Discussion, joined by:

Richard McFarland, Chief Regulatory Officer, ARMI/BioFabUSA

Speakers

J Kelly Ganjei
President and Chief Executive Officer
AmplifyBio
Kim Raineri
Chief Manufacturing and Technology Officer
AVROBIO
Edita Botonjic-Sehic
Director of Analytics, Digital Innovation
Pall Corporation
Dan Strange
Head of Cell Therapy Technology
TTP
Richard McFarland
Chief Regulatory Officer
ARMI